Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups

IMPORTANCE: Immune checkpoint inhibitors (ICIs) have improved survival outcomes of patients with advanced esophageal squamous cell carcinoma in both first- and second-line settings. However, the benefit of ICIs in patients with low programmed death ligand 1 (PD-L1) expression remains unclear. OBJECT...

Descripción completa

Detalles Bibliográficos
Autores principales: Yap, Dominic Wei Ting, Leone, Alberto Giovanni, Wong, Nicky Zhun Hong, Zhao, Joseph J., Tey, Jeremy Chee Seong, Sundar, Raghav, Pietrantonio, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857522/
https://www.ncbi.nlm.nih.gov/pubmed/36480211
http://dx.doi.org/10.1001/jamaoncol.2022.5816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857522/
https://www.ncbi.nlm.nih.gov/pubmed/36480211
http://dx.doi.org/10.1001/jamaoncol.2022.5816

Ejemplares similares